Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy

摘要

Background: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive urothelial carcinoma of the bladder confers only a modest survival advantage. Patients with pathologic progression on NAC have poor outcomes related to a delay in definitive surgical management.